



## King's Research Portal

DOI:

[10.2337/dc16-2331](https://doi.org/10.2337/dc16-2331)

*Document Version*

Peer reviewed version

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Ferrara, C. T., Geyer, S. M., Liu, Y.-F., Evans-Molina, C., Libman, I. M., Besser, R., Becker, D. J., Rodriguez, H., Moran, A., Gitelman, S. E., Redondo, M. J., & Type 1 Diabetes TrialNet Study Group (2017). Excess BMI in childhood: A modifiable risk factor for type 1 diabetes development? *Diabetes Care*, *40*(5), 698-701. <https://doi.org/10.2337/dc16-2331>

### **Citing this paper**

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### **General rights**

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### **Take down policy**

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

## **Excess body mass index in childhood: a modifiable risk factor for type 1 diabetes development?**

Excess BMI and risk for type 1 diabetes in childhood

Christine Therese Ferrara, MD, PhD<sup>1</sup>

University of California at San Francisco  
Division of Pediatric Endocrinology and Diabetes  
550 16th Street, 4th Floor, Box 0434  
San Francisco, CA 94143 (FedEX: 94158)  
Fax: (415) 476-5356  
Phone: (415) 476-3310  
christine.ferrara@ucsf.edu

Susan Michelle Geyer, PhD<sup>2</sup>  
Yuk-Fun Liu, MBSS<sup>3</sup>  
Carmella Evans-Molina, MD, PhD<sup>4</sup>  
Ingrid M. Libman, MD, PhD<sup>5</sup>  
Rachel Besser, MD<sup>6</sup>  
Dorothy J. Becker, MD<sup>5</sup>  
Henry Rodriguez, MD<sup>2</sup>  
Antoinette Moran, MD<sup>7</sup>  
Stephen E. Gitelman, MD<sup>1</sup>  
Maria J. Redondo, MD, PhD, MPH<sup>8</sup>  
Type 1 Diabetes TrialNet Study Group

<sup>1</sup>University of California, San Francisco

<sup>2</sup>University of South Florida

<sup>3</sup>Kings College London

<sup>4</sup>Indiana University School of Medicine

<sup>5</sup>Children's Hospital of Pittsburgh of UPMC

<sup>6</sup>Oxford University Hospitals NHS Foundation Trust

<sup>7</sup>University of Minnesota

<sup>8</sup>Baylor College of Medicine

**Objective:** The rising incidence of type 1 diabetes parallels an increased prevalence of obesity, yet the causal association remains inconclusive. Analyses often examine BMI at a single time point without emphasis on duration of BMI elevation. We aimed to determine the cumulative effect of elevated BMI over time on the progression to type 1 diabetes in youth, and to study the impact of age and sex on this relationship.

**Research Design and Methods:** We studied 1,117 pediatric participants in the TrialNet Pathway to Prevention cohort, i.e. autoantibody-positive relatives of patients with type 1 diabetes. Longitudinally accumulated BMI above the 85<sup>th</sup> age- and sex-adjusted percentile was calculated to generate a cumulative excess BMI (ceBMI) for each subject. Recursive partitioning analysis and multivariate modeling yielded sex and age-specific thresholds for ceBMI that confer the greatest risk for type 1 diabetes progression.

**Results:** ceBMI ranged from -10 to +15.1 kg/m<sup>2</sup> (median -1.86), with 0 corresponding to the CDC definition of elevated BMI ( $\geq 85^{\text{th}}$  BMI percentile). Higher ceBMI corresponded to significantly greater risk of progressing to type 1 diabetes ( $p=0.0006$ ). The increased risk of diabetes occurred at lower ceBMI values in children <12 years compared to older subjects, and in females versus males.

**Conclusions:** Elevated BMI is associated with increased risk of diabetes progression in pediatric autoantibody positive relatives, but the effect varies by sex and age. These data suggest that lifestyle modifications to lower BMI may delay the onset of type 1 diabetes and offers specific BMI thresholds for implementing these changes.

The global rise in incidence of type 1 diabetes has intensified efforts to identify modifiable risk factors in order to prevent or delay onset of clinical diabetes(1; 2). Although there are several genetic loci for type 1 diabetes susceptibility, heritability does not completely predict disease development, highlighting the role of other factors such as environmental influences(3). The parallel rise in obesity (4; 5) and type 1 diabetes incidence suggests a potential link between elevated body weight and type 1 diabetes progression(6-9). The “accelerator hypothesis” proposes that obesity-induced insulin resistance exacerbates the autoimmune-mediated beta cell destruction that characterizes type 1 diabetes (10). Obesity-induced insulin resistance may also accelerate clinical onset of type 1 diabetes by increasing insulin needs in those with already compromised insulin secretory capacity(11).

Data from the Diabetes Prevention Trial (DPT-1) indicate that insulin resistance is an independent risk factor for type 1 diabetes development(12). Moreover, the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS), a predictive tool of diabetes progression in the DPT-1 at-risk population, incorporates BMI as a critical component(13). More recently, however, BMI percentile was found to be only a minor risk factor for diabetes progression in antibody positive relatives of people with type 1 diabetes participating in the TrialNet Pathway to Prevention (PTP) cohort(14), although this study included both children and adults. Other prospective(15-17) and cross-sectional(11; 18; 19) studies report conflicting data for the role for body weight and obesity on type 1 diabetes progression, further highlighting the controversial nature of the accelerator hypothesis. The majority of prospective observational studies, however, limit their analysis to BMI at a single time point prior to disease diagnosis, and the impact of sustained BMI elevation measured longitudinally over time on risk of progression to type 1 diabetes remains unknown. In addition, the influence of sex and age on the relationship of BMI and progression to type 1 diabetes has yet to be explored.

Our overall objective was to determine the effect of sustained BMI elevation over time on the progression to type 1 diabetes in children at risk, and to study the impact of age and sex on this relationship. Here, we evaluated the longitudinal influence of cumulative excess BMI (ceBMI), a calculated aggregate measure of elevated BMI over time, on progression to type 1 diabetes in children participating in the TrialNet PTP cohort. Our evaluation focusing on the pediatric subjects of the PTP cohort allowed for unique investigation into sex- and age- specific influences on ceBMI and risk of type 1 diabetes progression.

#### Research Design and Methods:

**Subjects:** The TrialNet PTP cohort was established in 2001 and has been described previously(20). Briefly, nondiabetic first-degree relatives (ages 1–45 years) and second- or third- degree relatives (ages 1–20 years) of individuals with type 1 diabetes were enrolled and screened for presence of pancreatic islet antibodies. Antibody status was assessed according to the Diabetes Antibody Standardization Program(21). Participants were tested first for the presence of glutamic acid decarboxylase 65 (GAD65), insulin (IAA), or islet-antigen 2 (IA-2/ICA512) antibodies, and if positive, they were tested for islet cell antibodies (ICA) antibodies(22). Measurement of zinc transporter 8 (ZnT8) antibodies was initiated in 2004(23), and was consistently measured in the PTP cohort

starting in 2012. Confirmed autoantibody positive individuals were observed longitudinally with either semi-annual or annual monitoring, which included measurement of height and weight, and oral glucose tolerance testing (OGTT)(24).

A total of 3,285 eligible individuals were screened from March 2004 through June 2014, and were monitored for progression to diabetes through November 2015. To facilitate consistent and valid calculations of BMI percentiles and use of CDC criteria and guidelines to define overweight and obesity, we restricted our analysis cohort to only include participants age 2 to 18 years at their first BMI evaluation and who had at least two BMI measurements at monitoring visits before 20 years of age. Our resulting cohort consisted of a total of 1,117 subjects (Figure S1). One subject with severe morbid obesity and no other known conditions was excluded from final analysis to prevent limitation of generalizability of the results. All analyses were run with and without this subject to ensure that exclusion did not introduce bias, but data presented are without this subject. Baseline assessment for metabolic and anthropometric measurements is defined as the first visit with a BMI evaluation. Participants who later entered prevention trials were censored at the time of initial enrolment into the prevention trial.

Laboratory and anthropometric measurements: At each study visit, a standard protocol OGTT was performed and HbA1c was obtained. Glucose was measured using the glucose oxidase method(25). Diabetes was diagnosed according to American Diabetes Association criteria (fasting glucose  $\geq 126$ mg/dl, random glucose  $\geq 200$ mg/dl, 2 hour OGTT  $\geq 200$  mg/dl)(26), which must have been met on two occasions. A HbA1C  $\geq 6.5\%$  could be used as part of confirmatory testing(20).

BMI was calculated as weight (kg)/height(m<sup>2</sup>). The CDC 2000 growth charts ([www.cdc.gov/nccdphp/dnpao/growthcharts/resources/sas.htm](http://www.cdc.gov/nccdphp/dnpao/growthcharts/resources/sas.htm)) were used to obtain the value for 85<sup>th</sup> percentile for age- and sex- adjusted BMI for each subject at the time of each study visit. Cumulative excess BMI, hereby referred to as ceBMI, has been used previously as a measure of persistent elevation of BMI beyond the overweight threshold(27; 28). The weighted sums of the differences between the actual BMI and corresponding 85<sup>th</sup> BMI percentile for the sex and age at that evaluation were calculated using the method described by Lee et al (27) and Bouchard et al (28). Briefly, a ceBMI score was calculated by summing the difference calculated at each BMI assessment while accounting for the irregular timing between evaluations (equation 1):

$$ceBMI_{yr sj} = \sum_{i=0}^m \frac{(BMI_{t_i} - 85^{th} \text{percentile } BMI_{t_i}) + (BMI_{t_{i+1}} - 85^{th} \text{percentile } BMI_{t_{i+1}})}{2} \times \left( \frac{\text{number of days between } t_i \text{ and } t_{i+1}}{365.25} \right) \quad (1)$$

where  $ceBMI_{yr sj}$  = ceBMI-years for subject  $j$  in units kg/m<sup>2</sup>\*years, and  $m$  = the number of BMI evaluations for subject  $j$ . We further annualized  $ceBMI_{yr sj}$  to accommodate the irregular timing of BMI assessment in relation to time type 1 diabetes outcome or censoring in some subjects of our cohort (equation 2).

$$ceBMI_j = \frac{ceBMI_{yr sj}}{\frac{t_m - t_0}{365.25}} \quad (2)$$

where  $ceBMI_j$  is a value representing the annual average ceBMI in  $kg/m^2$  for subject  $j$  over the number of years subject  $j$  had  $m$  BMI evaluations,  $t_m$  is time in days at the last BMI measurement, and  $t_0$  is the time of first BMI evaluation.

To avoid confounding by weight loss that frequently precedes diagnosis of type 1 diabetes, for individuals who progressed to diabetes, the last BMI used was  $\geq 6$  months prior to the date of diagnosis

Statistical Considerations: Categorical variables were compared among groups by Pearson's  $X^2$  tests or Fisher Exact tests when cell sizes were insufficient. The majority of continuous variables summarized had skewed distributions and were compared between groups using nonparametric tests (Wilcoxon rank sum tests or Kruskal-Wallis tests, depending on the number of groups). Nonparametric Spearman rank correlation tests were used to assess correlation between continuous measures at baseline. Analyses of BMI were based on age- and sex-adjusted BMI percentiles. As such, baseline underweight status was defined as less than the 5<sup>th</sup> percentile, normal weight between the 5<sup>th</sup> and 85<sup>th</sup> percentile, overweight status at the 85<sup>th</sup> percentile or above, and obesity at the 95<sup>th</sup> percentile or above. Cumulative excess BMI was analyzed both as continuous measure as well as a dichotomized measure. Cumulative excess BMI  $\geq 0$  indicated a subject's BMI on average greater than or equal to the 85<sup>th</sup> percentile for their sex and age during the observation period.

The main clinical outcome for analysis was time to development of type 1 diabetes, defined as the time from the first BMI evaluation to the date of diagnosis. Those not diagnosed with type 1 diabetes were censored at their last date of follow up. In addition, those who during the course of their follow up enrolled in an interventional trial for the prevention of type 1 diabetes were censored on the date of their enrollment. Kaplan-Meier methods were used to assess differences in the time to type 1 diabetes distributions between groups of interest, and Cox proportional hazards models were used to assess the influence and significance of continuous and categorical variables. Assumptions for proportionality of hazards were tested for in these models. Given the known existence of risk factors and their potentially confounding effects, all time-to-event analyses were adjusted for age, sex, and whether or not subjects were single confirmed autoantibody positive versus multiple autoantibody positive at screening. To assess possible cut-points for ceBMI and age at first BMI evaluation in terms of their influence and stratification of risk on time to type 1 diabetes, we utilized recursive partitioning analyses(29) (rpart package in R). A model-based and iterative approach, specifically recursive partitioning analyses, was used to identify the "optimal" cut-point of the marker that best discriminated the outcome of interest, i.e. time to progression to type 1 diabetes.

We further evaluated each of the multivariable models with additional adjustment for high-risk HLA status (i.e. carrying the highest risk HLA DR3-DQ2/DR4-DQ8 genotype). HLA data were only available for a portion of the subjects and thus the main results presented without this adjustment. However, as a sensitivity analysis restricted to those with HLA data, we assessed the retention of results, both in terms of significance and impact when adjusted for HLA.

Overall, inferential tests were two-sided, with p-values  $< 0.05$  considered to be statistically significant. For interaction terms, p-values  $< 0.1$  were considered sufficient

for further exploration and evaluation of relationships given the sample size and number of events. All analyses were conducted in the statistical program R (version 3.1.2 for Windows).

## Results

**Demographics:** A total of 1,117 pediatric subjects between the ages of 2 and 18 years at the first BMI evaluation from the TrialNet PTP study were included in these analyses (Table 1). Of these, 220 subjects (20%) developed diabetes during the observation time. The median age at the first visit with BMI data available was 10.1 years (IQR: 6.7 to 13.3), and the median BMI percentile at their first evaluation was 63.8% (IQR: 36.6 to 84.8). Fourteen percent of individuals were overweight (BMI  $\geq$ 85<sup>th</sup>-<95<sup>th</sup> percentile) and 11% were obese ( $\geq$ 95<sup>th</sup> percentile).

There was a spectrum of ceBMI from -10 kg/m<sup>2</sup> to +15.1 kg/m<sup>2</sup> (median ceBMI -1.86 kg/m<sup>2</sup>; IQR: -3.6 to -0.03 m<sup>2</sup>/kg). Nearly 25% of subjects (273/1117) had ceBMI values  $\geq$ 0 kg/m<sup>2</sup> representing sustained excess BMI above the CDC threshold defining elevated BMI (overweight or obesity). There were no significant differences in age at first visit between those who were persistently overweight or obese compared to those of normal ceBMI (median ages 10.2 vs. 10.1 years, respectively,  $p=0.10$ ). Similarly, no significant differences in distribution of males to females based on ceBMI  $\geq$ 0 kg/m<sup>2</sup> versus <0 kg/m<sup>2</sup> ( $p=0.67$ ). Further, the continuous measure of ceBMI was not significantly different between males and females ( $p=0.54$ ).

Cumulative excess BMI influences progression to type 1 diabetes. In this pediatric cohort, we found that higher ceBMI was associated with significantly greater risk of progression to type 1 diabetes, which persisted after adjusting for age at first BMI evaluation, single versus multiple autoantibody status, and sex. For each 1 kg/m<sup>2</sup> increase in ceBMI, there was a 6.3% increased relative risk of type 1 diabetes progression (HR=1.063, 95% CI 1.03- 1.10,  $p=0.0006$ ) (Table 2).

To evaluate the influence of having an elevated BMI compared to remaining normal weight over time, ceBMI was dichotomized at the threshold for overweight status for sex and age (ceBMI  $\geq$ 0 kg/m<sup>2</sup> vs. <0 kg/m<sup>2</sup>). Again we found that individuals who on average were persistently overweight or obese during the observation time had significantly greater risk of progressing to type 1 diabetes than those who on average kept below the 85<sup>th</sup> percentile for BMI, even after adjusting for age, sex, and single versus multiple antibody (HR=1.63, 95% CI: 1.22-2.18,  $p=0.0009$ , Table 2).

### Age- and sex-specific ceBMI diabetes risk thresholds

Age at baseline was a significant independent risk factor for type 1 diabetes progression (HR=0.94,  $p=0.0006$ ), adjusted for ceBMI, sex, and antibody status. Interestingly, there was an interaction between age and sex together with ceBMI in relation to time to diabetes that achieved significance necessary to investigate age and sex specific strata ( $p=0.072$ ). Using recursive partitioning algorithms, we first identified the age cut-point defining greatest risk for type 1 diabetes progression. In both the combined cohort and in females alone, the cut-point for age that best differentiated subjects in terms of risk of progression to type 1 diabetes was just below 12 years at first BMI evaluation (all: 11.68 years; F: 11.77 years). In males, the optimal age cut-

point was similarly just under 12 years old (11.68 years) for subjects not in extremes of the ceBMI range (i.e. ceBMI -5.4 and 6.1). Furthermore, within each age group of <12 and  $\geq 12$  years, age was no longer a significant factor for males or females (p-value range 0.34-0.80). Therefore, it was determined that the influence of age on time to type 1 diabetes was well captured by this cut-point, and age dichotomized as  $\geq 12$  versus <12 years old at first BMI was used for subsequent analyses.

We again used recursive partitioning analysis as well as multivariable model-based diagnostics to identify cut-points for ceBMI that best differentiate risk for progression to diabetes, hereafter referred to as “ceBMI diabetes risk threshold”. We found that age modified the effect of ceBMI on diabetes risk. The ceBMI diabetes risk threshold was lower in children younger than 12 years of age than in individuals over 12 years of age, regardless of sex (ceBMI diabetes risk threshold of  $-1.4 \text{ kg/m}^2$  for <12 years old, vs. ceBMI diabetes risk threshold of  $4.6 \text{ kg/m}^2$  for  $\geq 12$ yo, Table 3). That is, the increase in type 1 diabetes risk occurs at lower levels of sustained excess BMI in younger than older children. On the contrary, older children needed to have a sustained excess BMI that was well over the overweight/obese threshold to significantly increase their risk of progression to diabetes.

We did observe an interaction between sex and ceBMI as a continuous variable (p=0.087), leading to an investigation of sex-specific ceBMI diabetes risk thresholds (Figure 1, Table 3). Males overall had a higher ceBMI diabetes risk threshold to increase risk of type 1 diabetes than females, suggesting an increased sensitivity to BMI in female subjects. Within age subsets, males who were  $\geq 12$  years at the time of their first BMI evaluation were detrimentally affected by excess body mass at a ceBMI diabetes risk threshold of  $5 \text{ kg/m}^2$  (Figure 1B), much higher than the ceBMI defining an overweight/obese state (Figure 1A). Similarly, in males who were <12 years old at their first BMI evaluation, a ceBMI diabetes risk threshold of  $2.5 \text{ kg/m}^2$  (Figure 1D), again above the overweight threshold (Figure 1C), best differentiated risk of type 1 diabetes. In contrast, females who were  $\geq 12$  years old at their first BMI evaluation had a ceBMI diabetes risk threshold of  $0 \text{ kg/m}^2$  that differentiated their risk (Figure 1F), consistent with the CDC definition of overweight/obese status (Figure 1E). Females <12 years old at their first evaluation had a lower ceBMI diabetes risk threshold compared to males of the same age, with a ceBMI diabetes risk threshold of  $-1.35 \text{ kg/m}^2$  (Figure 1H) suggesting that BMI percentiles below the overweight/obese threshold (Figure 1G) still increase type 1 diabetes risk in this subgroup.

Additional adjustment for the presence of the highest risk HLA genotype, i.e. DR3-DQ2/DR4-DQ8, demonstrated that age- and sex- group specific cutoffs were still significant within the models, and hazard ratios were consistent with models without this adjustment.

## Conclusion

The increasing incidence of type 1 diabetes over the last several decades underscores the urgent need to identify risk factors for disease progression(1; 2). Obesity is a known risk factor for type 2 diabetes, and the concept that obesity also accelerates progression to type 1 diabetes has gained interest(10; 30). Our data indicate that ceBMI, i.e. sustained elevation of BMI, is an important risk factor for type 1 diabetes progression, but that the effect varies by sex and age. In our cohort,



partitioning analyses identified an age cutoff of 12 years that stratified the effects of sustained elevation of BMI on risk of type 1 diabetes progression, and was used to define group-specific ceBMI diabetes risk thresholds. Older age diluted the effect of elevated BMI as demonstrated by the increased risk of type 1 diabetes in individuals <12 years of age at a ceBMI diabetes risk threshold of  $-1.4 \text{ kg/m}^2$ , lower than the ceBMI diabetes risk threshold of  $4.6 \text{ kg/m}^2$  in subjects older than 12 years of age (Table 3).

This age-dependent effect of sustained excess BMI on type 1 diabetes progression is present in both male and female sex strata, but ceBMI diabetes risk thresholds are additionally modified by sex (Table 3, Figure 1). Male subjects had higher ceBMI diabetes risk threshold defining increased risk for diabetes progression than females of the same age. A more severe degree of ceBMI (i.e. ceBMI diabetes risk threshold  $\geq 5 \text{ kg/m}^2$ ) determined increased risk of type 1 diabetes in males  $\geq 12$  years old, where in females  $\geq 12$  years old, any elevation above a ceBMI  $0 \text{ kg/m}^2$  (defining overweight or obese according to the CDC 85<sup>th</sup> percentile) enhanced risk. Similarly, in younger subjects <12 years of age, males required a higher ceBMI to increase risk of type 1 diabetes compared to females (ceBMI diabetes risk threshold  $\geq 2.5 \text{ kg/m}^2$  vs. ceBMI diabetes risk threshold  $\geq -1.35 \text{ kg/m}^2$ , respectively). Therefore, our data suggest that the detrimental effect of elevated BMI on progression to diabetes occurs at a lower BMI in girls than in boys, and BMI values below the threshold defining overweight can adversely affect progression to diabetes in girls under age 12 years old.

Past studies of the effects of BMI on type 1 diabetes have not yielded consistent results. In a case-control investigation, Kuchlubaer et al found that while birth weight was a risk factor for type 1 diabetes, BMI measured 5 years before diagnosis did not impact the age of disease onset(18). A study of the population participating in the SEARCH study demonstrated an association with earlier age of type 1 diabetes onset with higher BMI at diagnosis, but this was only seen in patients with lower fasting C-peptide levels indicative of baseline compromised beta-cell function(11). The Pittsburgh cross-sectional study similarly found no relationship between BMI at the time of type 1 diabetes diagnosis and age of disease onset(19)

Prospective studies of at-risk individuals have also failed to show a consistent impact of BMI on type 1 diabetes. The US Diabetes Autoimmunity Study in the Young (DAISY) found no association of progression to diabetes with BMI or weight(16). A study of the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) Study found that BMI standard deviation was a main independent predictor for diabetes, however after excluding obese subjects, this was no longer the case(17). A recent exploration of The Environmental Determinants of Diabetes in the Young (TEDDY) Study reported weight Z-score to be a risk factor for antibody seroconversion, but failed to show an effect on type 1 diabetes progression(15). Other prospective cohort studies of antibody-positive at risk subjects indicate that baseline insulin resistance, as assessed by HOMA, may increase risk of type 1 diabetes (8; 12; 31; 32). In fact, BMI at enrollment was found to be an independent risk factor for type 1 diabetes progression in DPT-1 participants, and is a component of the diabetes risk score which has been validated in other cohorts(13). However, a study of the both adult and pediatric participants of the TrialNet PTP cohort demonstrates only a minor effect of increased baseline BMI percentile on risk to disease progression, and no influence on antibody seroconversion(14).

Many of these prior prospective studies limited analyses to one measurement of BMI (e.g. birth weight, weight at cohort enrollment) without considering the interval values. Childhood is a dynamic time of rapid growth and pubertal development, and our analysis restricted to pediatric participants of the PTP permitted unique exploration of this time period. Growth hormone and sex hormones are not only known to alter insulin secretion and sensitivity, but are in turn altered by adipose tissue (33; 34). Our evaluation of ceBMI on type 1 diabetes progression uses an aggregate measure of elevated BMI over time among pediatric subjects in the PTP at risk cohort, thus taking advantage of longitudinal data. This model has been used in previous studies assessing persistent obesity on type 2 diabetes incidence and was demonstrated to be more accurate than using a single BMI measurement(27; 28). Our study is the first to apply this methodology to type 1 diabetes and revealed that ceBMI increased the risk of type 1 diabetes (HR=1.063, p=0.0006, Table 2). Beyond incorporation of longitudinal data, ceBMI measurement offers the additional advantage of an unrestricted upper limit compared to BMI percentile, and may offer greater resolution than a standard deviation or BMI Z-score.

A potential explanation for the differential effect of ceBMI on type 1 diabetes risk by sex, i.e.: different ceBMI diabetes risk thresholds, could be related to the discrepant correlation between BMI and adiposity in males and females(35; 36). This divergence may be more apparent during puberty as studies show that the correlation between BMI and percent body fat is nonlinear during this time, especially in non-obese individuals(37; 38). Lean body accrual in puberty is more apparent in males, further skewing the relationship of BMI to percent body fat compared to females. This is demonstrated by an increase in percentage body fat with each pubertal stage in females, yet in males the early peak in body fat is followed by a decline between Tanner stages 2-3(39). Our data reveal age- and sex-specific ceBMI diabetes risk thresholds, consistent with published literature where BMI captures adiposity and obesity differentially in males versus females throughout development. More sensitive anthropometric measures such as percent body fat or waist circumference (40) may be needed to supplement BMI measurements in deciphering sex-specific risk of obesity on type 1 diabetes.

The overall objective was to determine whether persistently elevated BMI is associated with progression to type 1 diabetes, rather than to determine whether fluctuations in BMI increase risk. While this study shows that sustained BMI excess is a type 1 diabetes risk factor, it cannot specifically address the effects of acute changes in BMI on disease onset. We did assess the intra-subject variability of BMI percentiles as well as the differences in visit-specific BMI excess above sex- and age-adjusted overweight/obese reference BMIs. A large majority of subjects (84%) remained classified as persistently above the overweight/obese threshold or persistently below this level for all BMI evaluations included in this analysis.

Our data suggest that puberty plays a significant role in defining ceBMI diabetes risk thresholds for type 1 diabetes progression. Limitations of this study include the lack of Tanner staging and sex hormone measurements which could elucidate mechanism of the identified age- and sex-specific ceBMI diabetes risk thresholds. An additional limitation of the dataset is a small number of diabetes events in some age and sex strata that may affect the precision of our estimates. Finally, it should be noted that our

study investigated an at-risk cohort of autoantibody-positive relatives of subjects of type 1 diabetes, and while heterogeneous, may not be broadly generalizable to the general population.

In summary, our results indicate that sustained elevation of BMI accelerates progression to type 1 diabetes in an at-risk pediatric population. Moreover, we demonstrate that CDC BMI cut-points at the 85<sup>th</sup> percentile may not appropriately define “excess BMI” in all pediatric subjects as it relates to type 1 diabetes development. Obesity is postulated to hasten progression to type 1 diabetes either by accelerated beta-cell loss or through mismatched insulin production and insulin demand. Future analysis to characterize the mechanisms underlying the effect of elevated BMI on type 1 diabetes risk, and the influence of age and sex are warranted. Our data imply that lifestyle and behavioral modifications may delay onset of disease, and importantly suggests age- and sex-specific ceBMI diabetes risk thresholds in which to implement such changes.

### Acknowledgements

Funding: The sponsor of the trial was the Type 1 Diabetes TrialNet Pathway to Prevention Study Group. Type 1 Diabetes TrialNet Pathway to Prevention Study Group is a clinical trials network funded by the National Institutes of Health (NIH) through the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases, and The Eunice Kennedy Shriver National Institute of Child Health and Human Development, through the cooperative agreements U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085465, U01 DK085453, U01 DK085461, U01 DK085463, U01 DK085466, U01 DK085499, U01 DK085504, U01 DK085505, U01 DK085509, U01 DK103180, U01-DK103153, U01-DK085476, U01-DK103266 and the Juvenile Diabetes Research Foundation International (JDRF). This work was also partially supported by the NIH grant K12-DK-094726 (C.T.F.) and U01-DK-103180-01 (M.J.R.). The contents of this Article are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or the JDRF.

Duality of Interest. No potential conflicts of interest relevant to this article were reported. Author Contributions. All authors are members of the Type 1 Diabetes TrialNet Study Group.

Author contributions: C.T.F. designed the analysis and study design, researched data and wrote the manuscript. S.M.G. analyzed the data and contributed statistical support and writing of the manuscript. C.E.M., Y.F.L., R.B., I.M.L., D.J.B., H.R., A.M. and S.E.G. reviewed and edited the manuscript, and contributed to discussion. M.J.R. contributed to data analysis design, interpretation of results and critically revised the manuscript. M.J.R. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Prior Presentation: This work was presented at the 76<sup>th</sup> Scientific Sessions of the American Diabetes Association, New Orleans, June 2016. It was also the recipient of the Modan Memorial Award.

## Figure Legends

**Figure 1. Age and sex-specific ceBMI diabetes risk thresholds compared to traditional overweight/obese thresholds.** Proportion type 1 diabetes free among pediatric subjects of the PTP cohort, comparing overweight/obese threshold, i.e. ceBMI  $\geq 0$  (based on 85<sup>th</sup> percentile for age and sex-adjusted BMI) (left panels) versus ceBMI diabetes risk thresholds identified by recursive partitioning algorithms (right panels). Male  $\geq 12$  years (A-B), male  $< 12$  years (C-D), females  $\geq 12$  years (E-F), females  $< 12$  years (G-H). All models adjusted for antibody number (single versus multiple).

## REFERENCES

1. Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltesz G, Group ES: Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. *Lancet* 2009;373:2027-2033
2. Lawrence JM, Imperatore G, Dabelea D, Mayer-Davis EJ, Linder B, Saydah S, Klingensmith GJ, Dolan L, Standiford DA, Pihoker C, Pettitt DJ, Talton JW, Thomas J, Bell RA, D'Agostino RB, Jr., Group SfdiYS: Trends in incidence of type 1 diabetes among non-Hispanic white youth in the U.S., 2002-2009. *Diabetes* 2014;63:3938-3945
3. Pierce BG, Eberwine R, Noble JA, Habib M, Shulha HP, Weng Z, Blankenhorn EP, Mordes JP: The Missing Heritability in T1D and Potential New Targets for Prevention. *J Diabetes Res* 2013;2013:737485
4. Ogden CL, Carroll MD, Kit BK, Flegal KM: Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. *Jama* 2012;307:483-490
5. Flegal KM, Carroll MD, Kit BK, Ogden CL: Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. *Jama* 2012;307:491-497
6. Betts P, Mulligan J, Ward P, Smith B, Wilkin T: Increasing body weight predicts the earlier onset of insulin-dependant diabetes in childhood: testing the 'accelerator hypothesis' (2). *Diabetic medicine : a journal of the British Diabetic Association* 2005;22:144-151
7. Lauria A, Barker A, Schloot N, Hosszufalusi N, Ludvigsson J, Mathieu C, Mauricio D, Nordwall M, Van der Schueren B, Mandrup-Poulsen T, Scherbaum WA, Weets I, Gorus FK, Wareham N, Leslie RD, Pozzilli P: BMI is an important driver of beta-cell loss in type 1 diabetes upon diagnosis in 10 to 18-year-old children. *European journal of endocrinology / European Federation of Endocrine Societies* 2015;172:107-113
8. Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC: Insulin resistance is a risk factor for progression to type 1 diabetes. *Diabetologia* 2004;47:1661-1667
9. Viner RM, Hindmarsh PC, Taylor B, Cole TJ: Childhood body mass index (BMI), breastfeeding and risk of Type 1 diabetes: findings from a longitudinal national birth cohort. *Diabetic medicine : a journal of the British Diabetic Association* 2008;25:1056-1061
10. Wilkin TJ: The accelerator hypothesis: weight gain as the missing link between Type I and Type II diabetes. *Diabetologia* 2001;44:914-922

11. Dabelea D, D'Agostino RB, Jr., Mayer-Davis EJ, Pettitt DJ, Imperatore G, Dolan LM, Pihoker C, Hillier TA, Marcovina SM, Linder B, Ruggiero AM, Hamman RF, Group SfDiYS: Testing the accelerator hypothesis: body size, beta-cell function, and age at onset of type 1 (autoimmune) diabetes. *Diabetes care* 2006;29:290-294
12. Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP: Role of insulin resistance in predicting progression to type 1 diabetes. *Diabetes care* 2007;30:2314-2320
13. Sosenko JM, Krischer JP, Palmer JP, Mahon J, Cowie C, Greenbaum CJ, Cuthbertson D, Lachin JM, Skyler JS, Diabetes Prevention Trial-Type 1 Study G: A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. *Diabetes care* 2008;31:528-533
14. Meah FA, DiMeglio LA, Greenbaum CJ, Blum JS, Sosenko JM, Pugliese A, Geyer S, Xu P, Evans-Molina C, Type 1 Diabetes TrialNet Study G: The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants. *Diabetologia* 2016;59:1186-1195
15. Elding Larsson H, Vehik K, Haller MJ, Liu X, Akolkar B, Hagopian W, Krischer J, Lernmark A, She JX, Simell O, Toppari J, Ziegler AG, Rewers M, Group TS: Growth and Risk for Islet Autoimmunity and Progression to Type 1 Diabetes in Early Childhood: The Environmental Determinants of Diabetes in the Young Study. *Diabetes* 2016;65:1988-1995
16. Lamb MM, Yin X, Zerbe GO, Klingensmith GJ, Dabelea D, Fingerlin TE, Rewers M, Norris JM: Height growth velocity, islet autoimmunity and type 1 diabetes development: the Diabetes Autoimmunity Study in the Young. *Diabetologia* 2009;52:2064-2071
17. Siljander HT, Hermann R, Hekkala A, Lahde J, Tanner L, Keskinen P, Ilonen J, Simell O, Veijola R, Knip M: Insulin secretion and sensitivity in the prediction of type 1 diabetes in children with advanced beta-cell autoimmunity. *European journal of endocrinology / European Federation of Endocrine Societies* 2013;169:479-485
18. Kuchlbauer V, Vogel M, Gausche R, Kapellen T, Rothe U, Vogel C, Pfaffle R, Kiess W: High birth weights but not excessive weight gain prior to manifestation are related to earlier onset of diabetes in childhood: 'accelerator hypothesis' revisited. *Pediatric diabetes* 2014;15:428-435
19. Cedillo M, Libman IM, Arena VC, Zhou L, Trucco M, Ize-Ludlow D, Pietropaolo M, Becker DJ: Obesity, islet cell autoimmunity, and cardiovascular risk factors in youth at onset of type 1 autoimmune diabetes. *The Journal of clinical endocrinology and metabolism* 2015;100:E82-86
20. Skyler JS, Greenbaum CJ, Lachin JM, Leschek E, Rafkin-Mervis L, Savage P, Spain L, Type 1 Diabetes TrialNet Study G: Type 1 Diabetes TrialNet--an international collaborative clinical trials network. *Annals of the New York Academy of Sciences* 2008;1150:14-24
21. Vehik K, Beam CA, Mahon JL, Schatz DA, Haller MJ, Sosenko JM, Skyler JS, Krischer JP, TrialNet Natural History Study G: Development of autoantibodies in the TrialNet Natural History Study. *Diabetes care* 2011;34:1897-1901
22. Mahon JL, Sosenko JM, Rafkin-Mervis L, Krause-Steinrauf H, Lachin JM, Thompson C, Bingley PJ, Bonifacio E, Palmer JP, Eisenbarth GS, Wolfsdorf J, Skyler JS, TrialNet Natural History C, Type 1 Diabetes TrialNet Study G: The TrialNet Natural

History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. *Pediatric diabetes* 2009;10:97-104

23. Yu L, Boulware DC, Beam CA, Hutton JC, Wenzlau JM, Greenbaum CJ, Bingley PJ, Krischer JP, Sosenko JM, Skyler JS, Eisenbarth GS, Mahon JL, Type 1 Diabetes TrialNet Study G: Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. *Diabetes care* 2012;35:1213-1218

24. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H, Type 1 Diabetes Trial Net Research G, European CPTSG: Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. *Diabetes care* 2008;31:1966-1971

25. Sosenko JM, Mahon J, Rafkin L, Lachin JM, Krause-Steinrauf H, Krischer JP, Cuthbertson D, Palmer JP, Thompson C, Greenbaum CJ, Skyler JS, Diabetes Prevention T-T, TrialNet Study G: A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants. *Pediatric diabetes* 2011;12:85-90

26. American Diabetes A: Standards of medical care in diabetes--2014. *Diabetes care* 2014;37 Suppl 1:S14-80

27. Lee JM, Gebremariam A, Vijan S, Gurney JG: Excess body mass index-years, a measure of degree and duration of excess weight, and risk for incident diabetes. *Arch Pediatr Adolesc Med* 2012;166:42-48

28. Bouchard DR, Porneala B, Janssen I, Langlois MF, Baillargeon JP, Fox CS, Meigs JB, D'Agostino RB, Sr., Pencina M, Hivert MF: Risk of type 2 diabetes and cumulative excess weight exposure in the Framingham Offspring Study. *J Diabetes Complications* 2013;27:214-218

29. Xu P, Krischer JP, Type 1 Diabetes TrialNet Study G: Prognostic Classification Factors Associated With Development of Multiple Autoantibodies, Dysglycemia, and Type 1 Diabetes-A Recursive Partitioning Analysis. *Diabetes care* 2016;39:1036-1044

30. Wilkin TJ: Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT): response to Bingley et al. *Diabetes care* 2008;31:e29

31. Bingley PJ, Mahon JL, Gale EA, European Nicotinamide Diabetes Intervention Trial G: Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). *Diabetes care* 2008;31:146-150

32. Meah FA, DiMeglio LA, Greenbaum CJ, Blum JS, Sosenko JM, Pugliese A, Geyer S, Xu P, Evans-Molina C, Type 1 Diabetes TrialNet Study G: The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants. *Diabetologia* 2016;

33. Moran A, Jacobs DR, Jr., Steinberger J, Cohen P, Hong CP, Prineas R, Sinaiko AR: Association between the insulin resistance of puberty and the insulin-like growth factor-I/growth hormone axis. *The Journal of clinical endocrinology and metabolism* 2002;87:4817-4820

34. Burt Solorzano CM, McCartney CR: Obesity and the pubertal transition in girls and boys. *Reproduction* 2010;140:399-410

35. Heo M, Wylie-Rosett J, Pietrobelli A, Kabat GC, Rohan TE, Faith MS: US pediatric population-level associations of DXA-measured percentage of body fat with four BMI metrics with cutoffs. *Int J Obes (Lond)* 2014;38:60-68
36. Stevens J, Ou FS, Cai J, Heymsfield SB, Truesdale KP: Prediction of percent body fat measurements in Americans 8 years and older. *Int J Obes (Lond)* 2016;40:587-594
37. Federico B, D'Aliesio F, Pane F, Capelli G, Rodio A: Body mass index has a curvilinear relationship with the percentage of body fat among children. *BMC Res Notes* 2011;4:301
38. Koren D, Marcus CL, Kim C, Gallagher PR, Schwab R, Bradford RM, Zemel BS: Anthropometric predictors of visceral adiposity in normal-weight and obese adolescents. *Pediatric diabetes* 2013;14:575-584
39. Wohlfahrt-Veje C, Tinggaard J, Winther K, Mouritsen A, Hagen CP, Mieritz MG, de Renzy-Martin KT, Boas M, Petersen JH, Main KM: Body fat throughout childhood in 2647 healthy Danish children: agreement of BMI, waist circumference, skinfolds with dual X-ray absorptiometry. *Eur J Clin Nutr* 2014;68:664-670
40. Wicklow BA, Becker A, Chateau D, Palmer K, Kozyrskij A, Sellers EA: Comparison of anthropometric measurements in children to predict metabolic syndrome in adolescence: analysis of prospective cohort data. *Int J Obes (Lond)* 2015;39:1070-1078

**Table 1. Demographics and baseline characteristics of PTP subjects.**

Characteristic	Overall cohort (n=1117)	Females (n=534)	Males (n=583)	p value*
Age at 1 <sup>st</sup> BMI evaluation (years)				
Median (IQR)	10.1 (6.7; 13.3)	9.6 (6.4; 13.3)	10.5 (7.1; 13.2)	0.24
Range	2.0 to 17.96	2.0 to 17.94	2.0 to 17.96	
Progressed to type 1 diabetes				
No	897	437	460	
Yes	220	97	123	
# of BMI evaluations/subject				
Median (IQR)	4 (3; 6)	4 (3; 6.75)	4 (3; 6)	0.84
Range	2 to 21	2 to 21	2 to 21	
Total follow-up time in study (years)				
Median (IQR)	2.51	2.52	2.49	0.13
Range	0.49 to 10.5	0.49 to 10.5	0.50 to 10.2	
Follow up time for BMI eval (years)				
Median	2.0	2.0	2.0	0.30
Range	0.39 to 10.2	0.39 to 9.99	0.49 to 10.2	
Race				
Caucasian	954	446	508	0.55
African American	27	13	14	
Asian	13	7	6	
American Indian/AK native	3	1	2	
Native HI/Pac.Islander	3	3	0	
Missing/unknown	117	65	53	
Ethnicity				
Non-Hispanic	914	436	478	0.15
Hispanic	161	87	74	
Missing/unknown	42	11	31	
BMI Percentile at 1 <sup>st</sup> BMI eval				
Median (IQR)	63.8 (36.6; 84.6)	63.9 (38.8; 84.6)	63.5 (34.2; 84.8)	0.76
Range	0.0 to 99.9	0.2 to 99.7	0.0 to 99.9	
BMI Category at 1 <sup>st</sup> BMI eval				
Underweight	47	25	22	0.84
Normal Weight	795	378	417	
Overweight	151	74	77	
Obese	124	57	67	
Cumulative excess BMI (ceBMI)				
Median (IQR)	-1.88(-3.6; -0.04)	-1.95 (-3.5;-0.2)	-1.8 (-3.7; 0.032)	0.54
Range	-10.0 to 15.1	-9.2 to 15.1	-10.0 to 14.7	
<0	844	407	437	0.67
≥0	273	127	146	
HLA DR3/4 status				
Neither	161	80	81	0.74
DR3 and/or DR4	787	377	410	
Missing	169	77	92	
Antibody status at 1 <sup>st</sup> BMI eval				
Single Ab+	367	193	174	0.03
Multiple Ab+	750	341	409	
OGTT result at 1 <sup>st</sup> BMI eval				
Normal	769	371	398	0.34
Abnormal†	250	111	139	
Missing	98	52	46	



\* p-values reflect differences by sex. †Abnormal OGTT defined as fasting blood glucose 100-125mg/dl and/or 2-hour glucose 140-199mg/dl.

**Table 2. ceBMI increases risk of progression to type 1 diabetes**

	All subjects		Male		Female	
	HR (95% CI)	p value	HR (95% CI)	p value	HR (95% CI)	p value
<b>ceBMI</b>	1.063(1.03- 1.10)	0.0006	1.09 (1.04 -1.15)	0.0005	1.04(0.99-1.09)	0.11
<b>ceBMI <math>\geq 0</math>*</b>	1.63 (1.22-2.18)	0.0009	1.60(1.08-2.36)	0.018	1.74(1.12-2.69)	0.013

Hazard ratios corresponding 95% confidence intervals, and p-values for various multivariable models for time to type 1 diabetes by age- and sex-based groups. All models adjusted for age at first BMI evaluation, sex, and whether or not they were single versus multiple Ab+ at their first BMI evaluation, except for models that are specific to one of those groups. \* ceBMI $\geq 0$  represents CDC sex and age specific BMI threshold for the 85<sup>th</sup> percentile.

**Table 3. Age- and sex-specific ceBMI diabetes risk thresholds**

	Age	OVERWEIGHT/OBESE THRESHOLD*			DIABETES RISK THRESHOLD†		
		ceBMI	HR (95% CI)	p value	ceBMI	HR (95% CI)	p value
<b>Overall</b>	≥12	0	1.64(0.92-2.92)	0.095	4.6	2.92 (1.41-6.04)	0.004
	<12	0	1.68(1.2-2.35)	0.03	-1.4	1.78 (1.30-2.44)	0.0003
<b>Male</b>	≥12	0	1.11 (0.50-2.45)	0.79	5	3.62 (1.38-9.52)	0.009
	<12	0	1.85 (1.17-2.90)	0.008	2.5	2.83 (1.58-5.08)	0.0005
<b>Female</b>	≥12	0	2.91 (1.15-7.39)	0.024	0	2.91 (1.15-7.39)	0.024
	<12	0	1.54 (0.93-2.57)	0.095	-1.35	1.70 (1.09-2.66)	0.02

Hazard ratios corresponding 95% confidence intervals, and p-values for various multivariable models for time to type 1 diabetes by age- and sex-based group using age- and sex-specific ceBMI cut-points. All models adjusted for age at first BMI evaluation, sex, and whether or not they were single versus multiple Ab+ at their first BMI evaluation, except for models that are specific to one of those groups. \* ceBMI<sub>≥0</sub> represents CDC sex and age specific BMI threshold for the 85<sup>th</sup> percentile. † ceBMI<sub>≥</sub> values identified by recursive partitioning within particular strata to give group-specific diabetes risk thresholds